Tests PAP breathing device in stroke patients with sleep apnea
Tests a breathing machine against usual care in adults with stroke and sleep apnea.
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Registry title
- The Recovery in Stroke Using PAP Study
- Status
- Recruiting
- People taking part
- 360 people, planned
- Started
- 1 Sept 2019
- Planned end
- Oct 2025
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- PAP
- HLE
- Record updated
- 5 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who just had an ischemic stroke and have moderate or severe obstructive sleep apnea (OSA). It compares PAP treatment with usual care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke confirmed by brain imaging within 48 hours of symptom onset, and within 5 days of the first neurologic symptoms. Moderate or severe OSA (obstructive apnea-hypopnea index AHI of 15 or higher).
- Earlier treatment
- People who used prescribed PAP for OSA in the past cannot join.
- Biomarker or test result
- Sleep test result: obstructive apnea-hypopnea index (AHI) of 15 or higher.
Main reasons for not taking part
- Past use of prescribed PAP for OSA
- A suspected sleep disorder other than OSA, such as narcolepsy
- Life expectancy under 6 months
- Needs mechanical ventilation
- Cannot give their own informed consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Having an acute ischemic stroke with brain imaging within 48 hours of symptoms onset
- Being within 5 days of neurologic symptoms onset
- Moderate (15 =< overall AHI < 30) /severe (overall AHI >= 30) OSA, thus with an obstructive apnea-hypopnea index AHI >= 15
Who cannot take part
- Inability to provide their own informed consent. To enhance the generalizability of our study, all stroke severity will be included. However, we will exclude patients who cannot provide their own consent. This is because patients will need to participate actively in the protocol with a behavioral intervention. An assessment of the patient's competence to provide consent will be made based on published recommendations
- Suspected sleep disorder other than OSA (e.g., narcolepsy) (because such patients should be referred for a formal PSG in a sleep laboratory)
- Past use of prescribed PAP for OSA
- Life expectancy is less than 6 months (e.g., hospice patients)
- Patients who require mechanical ventilation (because such patients could not participate in the intervention protocol)
- Non-English language patients (because the intervention strategy involves forming a relationship between the patient and research staff)
- Central sleep apnea with > 50% of respiratory events classified as central apnea
- Resting oxygen saturation < 90%
Where in United States
- Yale UniversityNew Haven, United StatesContact: Klar Yaggi, MDTaking people
About the trial
What the trial wants to find out
The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.
The 4 groups in the trial
- PAP treatment- AcuteTreatment being tested
Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
Treatment: PAP and HLE
- Usual Care (HLE)Existing treatment, for comparison
All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
Treatment: HLE
- PAP treatment- SubacuteTreatment being tested
Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
Treatment: PAP and HLE
- Exploratory armOther group
Non-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) \<15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI.
Treatment: HLE
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Recovery in Stroke Using PAP Study
- Plain-language title
- Tests PAP breathing device in stroke patients with sleep apneaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 September 2025